Search
forLearn
5 / 801 resultslearn HT-B
learn heptyl glucoside
learn histidine
learn AHAs
Research
5 / 137 resultsresearch Solubilizing steroidal drugs by β-cyclodextrin derivatives
Using β-cyclodextrin derivatives improves the solubility and bioavailability of steroidal drugs.
research Enhancement of In Vitro Hair Shaft Elongation in Follicles Stored in Buffers That Prevent Follicle Cell Apoptosis
Storing hair follicles in special buffers with added protective substances can increase hair growth and reduce cell death.
research Developing New Graft Holding Solutions:In VitroEvaluation of Bioactive Molecules Identifies Vitamin B12 as Micrograft Stabilizing Substance
Vitamin B12 improves the health and growth of hair micrografts.
research Enhancement of In Vitro Hair Shaft Elongation in Follicles Stored in Buffers That Prevent Follicle Cell Apoptosis
Storing hair follicles in a special buffer with certain inhibitors can increase hair growth and improve transplant results.
research 918 Tissue engineered human hair follicles from genetically, environmentally and extrinsically reprogrammed dermal papilla cells
Researchers developed a method to grow human hair follicles using 3D-printed skin models and modified cells.
Community Join
5 / 1000+ resultscommunity How did you feel about HIMS?
The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI-115 Australian Phase 1 Trial completed?
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.